Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera

AIM: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi(®)) was approved in the US to treat adults with PV. The purpose of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerds, Aaron T, Castro, Claudia, Snopek, Frank, Flynn, Megan M, Ellis, Alexandra G, Manning, Meredith, Urbanski, Ray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690394/
https://www.ncbi.nlm.nih.gov/pubmed/37531245
http://dx.doi.org/10.57264/cer-2023-0066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690394/
https://www.ncbi.nlm.nih.gov/pubmed/37531245
http://dx.doi.org/10.57264/cer-2023-0066

Ejemplares similares